Clinical Trial Update: Study to Compare Zoladex™ 10.8 mg With Zoladex 3.6 mg in Pre-menopausal Women With Breast Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial comparing Zoladex 10.8 mg with Zoladex 3.6 mg in pre-menopausal women with breast cancer has completed with results posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Zoladex (goserelin)

Snippet

Sponsor: AstraZeneca | Conditions: Breast Cancer | Phase 3 | Status: COMPLETED | Results posted: 2014-01-10